In the latest session, Lyell Immunopharma Inc (NASDAQ: LYEL) closed at $2.41 up 0.42% from its previous closing price of $2.40. On the day, 1335281 shares were traded.
Ratios:
For a deeper understanding of Lyell Immunopharma Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.07 and its Current Ratio is at 16.07. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on August 28, 2023, Downgraded its rating to Neutral and sets its target price to $5 from $15 previously.
On November 14, 2022, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also lowered its target price recommendation from $15 to $7.
Goldman Downgraded its Buy to Neutral on November 11, 2022, whereas the target price for the stock was revised from $13 to $7.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 15 ’23 when Klausner Richard sold 58,020 shares for $2.28 per share. The transaction valued at 132,286 led to the insider holds 930,880 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4710.62 while its Price-to-Book (P/B) ratio in mrq is 0.93.
Stock Price History:
Over the past 52 weeks, LYEL has reached a high of $3.97, while it has fallen to a 52-week low of $1.32.
Shares Statistics:
A total of 253.96M shares are outstanding, with a floating share count of 117.74M. Insiders hold about 53.66% of the company’s shares, while institutions hold 27.94% stake in the company.
